LifeTech Scientific Corporation (HK:1302)
:1302
Want to see HK:1302 full AI Analyst Report?
1302 Stock Chart & Stats
HK$1.58
HK$0.01(0.75%)
At close: 4:00 PM EST
HK$1.58
HK$0.01(0.75%)
Day’s Range― - ―
52-Week RangeHK$1.47 - HK$2.44
Previous CloseN/A
Volume6.38M
Average Volume (3M)26.58M
Market Cap
HK$7.17B
Enterprise ValueHK$5.55B
Total Cash (Recent Filing)HK$1.20B
Total Debt (Recent Filing)HK$8.04M
Price to Earnings (P/E)45.2
Beta0.89
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding4,631,712,400
10 Day Avg. Volume33,345,600
30 Day Avg. Volume26,582,987
Financial Highlights & Ratios
PEG Ratio-1.21
Price to Book (P/B)1.79
Price to Sales (P/S)4.58
P/FCF Ratio12.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$1.53B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageExtremely low leverage materially reduces solvency and refinancing risk, giving management durable financial flexibility. This conservatism supports sustained R&D, targeted commercial expansion or M&A without stressing liquidity, improving resilience over the next 2–6 months.
Top-line Re-accelerationA sharp revenue re-acceleration indicates stronger product adoption or expanded procedure penetration, which can drive longer-term scale benefits. If sustained, this growth supports better fixed-cost absorption and the potential to restore margins and market share over several quarters.
Improved Free Cash Flow GenerationRobust FCF and high conversion versus net income strengthen internal funding capacity for capex, clinical studies, and commercialization. Strong cash generation enhances strategic optionality and reduces reliance on external financing, a durable advantage for capital allocation decisions.
Bears Say
Margin CompressionSustained and material margin erosion reduces the firm's ability to convert revenue into earnings and weakens long-term profitability. This suggests pricing pressure, rising costs, or adverse product-mix shifts that can constrain reinvestment and shareholder returns over multiple quarters.
Weakening Return On Equity / Capital EfficiencyA sharp decline in ROE signals deteriorating capital efficiency and indicates the business is generating much lower returns on invested equity. Persistently low ROE can limit ability to attract capital, pressure management to change strategy, and highlight execution or margin issues.
Volatile Cash Conversion / Operating Cash QualityWide variability in cash conversion increases uncertainty about sustainable cash generation; working-capital swings or timing effects can mask underlying profitability. This variability can constrain discretionary spending and makes planning for R&D, commercialization, or buybacks less reliable.
LifeTech Scientific Corporation News
1302 FAQ
What was LifeTech Scientific Corporation’s price range in the past 12 months?
LifeTech Scientific Corporation lowest stock price was HK$1.47 and its highest was HK$2.44 in the past 12 months.
What is LifeTech Scientific Corporation’s market cap?
LifeTech Scientific Corporation’s market cap is HK$7.17B.
When is LifeTech Scientific Corporation’s upcoming earnings report date?
LifeTech Scientific Corporation’s upcoming earnings report date is Aug 28, 2026 which is in 89 days.
How were LifeTech Scientific Corporation’s earnings last quarter?
LifeTech Scientific Corporation released its earnings results on Mar 31, 2026. The company reported HK$0.023 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.023.
Is LifeTech Scientific Corporation overvalued?
According to Wall Street analysts LifeTech Scientific Corporation’s price is currently Overvalued.
Does LifeTech Scientific Corporation pay dividends?
LifeTech Scientific Corporation does not currently pay dividends.
What is LifeTech Scientific Corporation’s EPS estimate?
LifeTech Scientific Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LifeTech Scientific Corporation have?
LifeTech Scientific Corporation has 4,631,712,400 shares outstanding.
What happened to LifeTech Scientific Corporation’s price movement after its last earnings report?
LifeTech Scientific Corporation reported an EPS of HK$0.023 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of LifeTech Scientific Corporation?
Currently, no hedge funds are holding shares in HK:1302
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LifeTech Scientific Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.71%
12-Months-Change
Fundamentals
Return on Equity
4.06%
Trailing 12-Months
Asset Growth
7.05%
Trailing 12-Months
Company Description
LifeTech Scientific Corporation
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The company operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. Its products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, Heart, and Konara-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; delivery systems, such as Fustar steerable and SteerEase introducers; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; LawMax dilators; and SeQure snare systems, as well as pacemakers. The company is also involved in the biomedical research and development; manufacturing and trading of materials for hemp; staff training and internal personnel management business; information consulting for investors; and manufacturing and trading of medical devices, as well as technical, consulting, and technology services. It has operations in Mainland China, India, rest of Asia, Europe, South America, Africa, and internationally. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, the People's Republic of China.
Technical Analysis
MicroPort Scientific
―
Peijia Medical Ltd.
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
Options Prices
Currently, No data available
---